Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Nektar Therapeutics Stock Quote

Nektar Therapeutics (NASDAQ: NKTR)

$1.57
(-6.0%)
-$0.10
Price as of April 15, 2024, 4:00 p.m. ET

Nektar Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
NKTR +69.69% -94.97% -45.00% -55%
S&P +22.34% +74.52% +11.78% +1,017%

Nektar Therapeutics Company Info

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

News & Analysis

The Fool has written over 100 articles on Nektar Therapeutics.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.